Indivior stock gains on raised 2026 outlook and strong Sublocade growth

Indivior (ISIN GB00BYZ0C031) stock has attracted renewed investor attention after the company reported sharply higher earnings for the second quarter of 2026 and raised its full-year guidance, while the Nasdaq-listed shares recently closed at 35.05 US dollars on September 1, 2026 according to market data.

Q2 2026 earnings show strong growth

According to an analysis published by Zacks on September 2, 2026, Indivior delivered adjusted earnings of 1.15 US dollars per share in the second quarter of 2026, an increase of 125.5 percent year over year and above the consensus estimate of 0.97 US dollars.

The same Zacks report states that total revenues in the second quarter of 2026 rose 13.6 percent year over year to 343 million US dollars, supported mainly by strong demand for the long-acting opioid use disorder treatment Sublocade.

Within that total, Sublocade generated net revenues of 253 million US dollars in the quarter, which Zacks notes was a quarterly record and represents 21 percent year-over-year growth, underscoring the product’s central role in Indivior’s expansion.

Sublocade drives patient and revenue momentum

Indivior’s U.S. Sublocade revenues increased 22 percent year over year in the second quarter of 2026 to 238 million US dollars, supported by dispense unit volume growth, favorable price and mix effects and gross-to-net adjustments, according to the Zacks analysis.

The company also reported an 18 percent year-over-year increase in Sublocade dispense unit volume in the quarter, reflecting robust underlying demand for the therapy.

Zacks highlights that the second quarter of 2026 brought record new patient starts for Indivior, with approximately 32,816 patients beginning Sublocade treatment, and that as of June 30, 2026, more than 545,000 U.S. patients had been prescribed Sublocade since its launch.

Broader portfolio and regional trends

Beyond Sublocade, Indivior’s U.S. sublingual and other product revenues increased in the second quarter of 2026 to 57 million US dollars, compared with 52 million US dollars in the prior-year quarter, according to Zacks.

Rest of World revenues, by contrast, declined 6.5 percent year over year to 43 million US dollars in the same period, illustrating a mixed regional picture even as U.S. operations expanded.

Zacks reports that overall U.S. revenues in the second quarter of 2026 rose to 300 million US dollars, up from 256 million US dollars a year earlier, underscoring that the growth in Indivior’s largest market more than offset softer performance elsewhere.

Profitability, balance sheet and share repurchases

Indivior continued to improve its profitability profile in the second quarter of 2026, with adjusted operating expenses declining 33 percent year over year to 112 million US dollars, as reported by Zacks.

The same analysis indicates that adjusted EBITDA surged 111 percent year over year to 186 million US dollars in the second quarter of 2026, reflecting both revenue growth and disciplined cost management.

On the balance sheet side, Zacks notes that Indivior ended the quarter with 249 million US dollars in cash and investments, compared with 201 million US dollars as of March 31, 2026, and that the company repurchased about 4.7 million shares during the quarter for 175 million US dollars at an average price of 37.52 US dollars.

Raised 2026 guidance supports investor sentiment

Reflecting stronger-than-expected commercial performance, Indivior raised its full-year 2026 financial guidance, which Zacks reports as a new net revenue range of 1.295 billion to 1.365 billion US dollars, up from the previous 1.215 billion to 1.285 billion US dollars.

The guidance for total Sublocade net revenues in 2026 was also lifted to a range of 1.01 billion to 1.05 billion US dollars from the prior 950 million to 990 million US dollars, implying approximately 20 percent year-over-year growth at the midpoint, according to the same Zacks report.

Indivior’s adjusted EBITDA outlook for 2026 was increased to a range of 700 million to 740 million US dollars, compared with the previous 620 million to 660 million US dollars, while the company maintained its adjusted operating expense guidance at 430 million to 450 million US dollars.

Analyst view and share performance context

Zacks assigns Indivior Pharmaceuticals Inc. a rank of 2, which corresponds to a Buy rating, and describes the stock’s overall VGM Score as A, indicating a combination of strong growth and value characteristics despite weaker momentum metrics.

The same article notes that Indivior shares were down 5.3 percent in the month following the second-quarter 2026 earnings release, underperforming the S&P 500 over that period even as estimates for the company were revised upward.

Despite that short-term underperformance, the upgraded guidance and improving profitability metrics suggest that the investment case for Indivior now hinges on whether the company can sustain double-digit revenue growth and strong Sublocade momentum through the rest of 2026.

Product focus: Sublocade in opioid use disorder treatment

Sublocade, Indivior’s extended-release injectable buprenorphine formulation for the treatment of moderate to severe opioid use disorder, has become the company’s flagship product and the key driver of recent financial performance.

The second-quarter 2026 data cited by Zacks, including 21 percent year-over-year growth in Sublocade net revenues to 253 million US dollars and record new patient starts, underline how central Sublocade is to Indivior’s strategy in the U.S. and internationally.

For investors, the sustained growth in Sublocade revenues and patient numbers is crucial because the product’s performance underpins the raised 2026 guidance ranges and the company’s ability to continue funding share repurchases and potential further investments in its central nervous system and addiction treatment pipeline.

Indivior stock and market data

Indivior Pharmaceuticals Inc. is listed on the Nasdaq under the ticker symbol INDV, and according to recent data from Yahoo Finance the shares closed at 35.05 US dollars on September 1, 2026, with the trailing total returns as of that date reflecting the stock’s performance relative to the S&P 500 benchmark.

In addition, an interactive chart overview indicates that Indivior shares recently traded around 34.56 US dollars, representing a decline of approximately 1.06 percent on the day in that snapshot, providing investors with a sense of short-term volatility around the stock.

Looking ahead to the coming months, the combination of raised guidance, strong Sublocade momentum and an analyst Buy rating sets the frame in which Indivior stock will likely be judged by the market, particularly if the company continues to deliver on its financial targets for 2026.

Indivior master data and key figures

• Company: Indivior Pharmaceuticals, Inc.
• ISIN: GB00BYZ0C031
• Ticker: INDV
• Trading venue: Nasdaq
• Price (as of September 1, 2026): 35.05 USD
• Sector / Industry: Healthcare / Pharmaceuticals
• Index membership: Nasdaq benchmark